

# ICU

## MANAGEMENT & PRACTICE

THE OFFICIAL MANAGEMENT JOURNAL OF ISICEM

VOLUME 16 - ISSUE 2 - SUMMER 2016



Visit us at  
**#ESALondon**  
**C140**

# Safety

### PLUS

Biomarkers for Acute Kidney Injury

Early Diagnosis and Prediction of AKI

Robots in Anaesthesia

Perioperative Respiratory Management of Morbidly Obese Patients

Chain of Survival after Out-of-Hospital Cardiac Arrest

Potential Nutritional Strategies to Reduce Muscle Wasting in Early Critical Illness

The Future of ICU Prediction Scores in the Era of "Big Data"

Vodcasting

Podcasting

Resource Allocation in Healthcare

Interview: Prof. Sharon Einav, European Society of Anaesthesiology

Country Focus: Sri Lanka





### Frédéric Barbut\*

Head  
National Reference Laboratory  
for *Clostridium difficile*  
Clinical Research Group  
« EPIDIFF »  
Faculty of Medicine  
Pierre and Marie Curie University  
AP-HP Saint-Antoine Hospital  
Paris, France

frederic.barbut@sat.aphp.fr



### Javier Cobo

Head of Section  
Department of Infectious  
Diseases  
University Hospital Ramón y Cajal  
Ramón y Cajal Institute of Health  
Research (IRYCIS)  
Madrid, Spain

javier.cobo@salud.madrid.org

# CLOSTRIDIUM DIFFICILE

## A PUBLIC HEALTH THREAT THAT SHOULD BE ROUTINELY INCLUDED WITHIN CARE QUALITY AND PATIENT SAFETY PROGRAMMES

This paper provides an overview of the evidence confirming that CDI independently increases mortality risk in hospitalised patients, and argues for system-wide implementation of specific actions, including care bundles for management (not only infection control) and mandatory surveillance, to improve the quality of CDI care, and thereby reduce morbidity and mortality, in alignment with European policy initiatives.

Patient safety, defined as the freedom for patients from unnecessary or potential harm associated with healthcare (Council of the European Union 2009), is a central component of healthcare quality. Healthcare-associated infections (HAIs) are a leading threat to patient safety. On average, 6% of patients in European acute care hospitals have at least one HAI (European Centre for Disease Prevention and Control [ECDC] 2013). Annually these infections are estimated to cause 37,000 deaths and to incur costs of over €5.5 billion (Committee on the Environment, Public Health and Food Safety 2013). In 2009 the European Council recommended that Member States implement various measures to improve patient safety and HAI prevention and control in particular (Council of the European Union 2009). The implementation of these measures has been supported by the European Union Network for Patient Safety and Quality of Care Joint Action ([pasq.eu](http://pasq.eu)). Progress has been made (European Commission 2012; European Commission 2014), and there is a raised level of awareness about patient safety at the political level. Nevertheless, the European Parliament has urged the Commission and Member States to step up their efforts and to place the issue near the top of the political agenda (Committee on the Environment, Public Health and Food Safety 2013), and the European Council has invited the Commission to continue supporting improvements in patient safety and HAIs and the Member States to intensify their efforts in these areas (Council of the European Union 2014). Specific considerations include the

setting of national targets, resourcing, education and training of healthcare professionals, the promotion of good practice, information provision to patients, disease surveillance and research support.

Although figures vary between countries, *Clostridium difficile* (*C. difficile*) infection (CDI) accounts for almost 4% of all HAIs in Europe, and *C. difficile* accounts for 5.4% of isolated pathogens, being the eighth most common (ECDC 2013). CDI is increasingly common in many countries and the estimated annual number of 124,000 cases across Europe (ECDC 2013) is likely to be an underestimate owing to under-diagnosis (ECDC 2013; Davies et al. 2014). In the United States, a multistate prevalence survey concluded that *C. difficile* was the most commonly reported pathogen, causing 12% of all HAIs (Magill et al. 2014). The Centers for Disease Control and Prevention (CDC) estimates that 453,000 CDI cases occur annually in the U.S. (Lessa et al. 2015) and categorises CDI in the highest priority category of antimicrobial resistance threats (CDC 2013). In a systematic assessment of antimicrobial resistant threats based on 10 criteria, the public health agency of Canada also defined *C. difficile* as the second most important national priority (Garner et al. 2015). CDI typically adds approximately €4000–14,000 to inpatient costs, mainly as a result of extended hospitalisation (Weigand et al. 2012; Asensio et al. 2015; Heimann et al. 2014).

CDI has been the focus of comprehensive and effective national-level control and surveillance interventions in some countries (e.g. United

### Oliver A. Cornely

Professor  
Head of Translational Platform and Principal Investigator  
Department I of Internal Medicine  
Clinical Trials Centre Cologne [ZKS Köln BMBF 01KN1106]  
Cologne Excellence Cluster on Cellular Stress Responses in  
Aging-Associated Diseases  
University of Cologne  
Cologne, Germany

oliver.cornely@uk-koeln.de

### Ed J. Kuijper

Professor of Experimental Bacteriology  
Department of Medical  
Microbiology  
Leiden University Medical Centre  
Leiden, the Netherlands

Head  
National Reference Centre for *C. difficile*  
the Netherlands

Coordinator  
European CDI Surveillance Network

E.J.Kuijper@lumc.nl

### Nicola Petrosillo

Director of the Clinical and Research Department  
National Institute for Infectious Diseases Lazzaro Spallanzani-  
INMI IRCCS  
Rome, Italy

nicola.petrosillo@inmi.it

\*corresponding author

Kingdom), but remains under-recognised as a public health threat in many others. Indeed a discrepancy exists whereby, in many countries, efforts have focussed on multi-drug resistant Gram-negative pathogens and methicillin-resistant *Staphylococcus aureus*, while CDI presents a greater threat to public health (CDC 2013).

### CDI and Mortality

Patients who acquire CDI in healthcare facilities are at high risk of death. Rates of all-cause 30-day mortality are estimated at 3–30% among all patients (Weigand et al. 2012; Wenisch et al. 2012; Hensgens et al. 2013; Schmid et al. 2013; Planche et al. 2013), and reach 40% among patients who undergo emergency surgery for fulminant CDI (Bhangu et al. 2012). However, as CDI is most common among patients who are elderly and suffering from severe underlying illnesses (Bauer et al. 2011), specific studies were necessary to confirm its independent contribution to the risk of death.

A European-wide epidemiological study conducted in 2008 found that CDI caused or contributed to death in 9% of 455 infected patients within 3 months of diagnosis. Expressed differently, CDI caused or contributed to 40% of all deaths occurring within 3 months (Bauer et al. 2011). More recently a large prospective cohort study in nine hospitals in the Netherlands showed that even in an endemic situation (i.e. in the absence of outbreaks), CDI independently increased the risk of 30-day mortality by 2.5-fold (95% confidence intervals [CI] 1.4–4.3), as compared with patients without diarrhoea, after adjustment for age, sex and underlying diseases (Fig. 1) (Hensgens et al. 2013). Similarly a single-centre, prospective cohort study in Austria found a relative risk for pre-discharge death among patients with CDI of 2.74 (95% CI 1.82–4.10;  $p < 0.0001$ ), as compared with patients without CDI (Wenisch et al. 2012).

In the Netherlands, patients with CDI were more likely to die within 30 days (hazard ratio 1.6; 95% CI 0.9–2.8) than were controls who had diarrhoea but a negative test for *C. difficile* toxins—indicating that CDI, rather than diarrhoea per se, increased the mortality risk (Hensgens et al. 2013). Similarly, a prospective multicentre study of over 6500 CDI episodes in the UK showed that patients whose unformed faecal samples tested positive for the *C. difficile* toxins had a higher 30-day mortality (after multivariate analysis to account for




Figure 1. Mortality Rate of Patients with *Clostridium difficile* Infection (CDI) and a Matched Cohort. Reproduced from Hensgens et al. (2013) with permission

confounding factors) than those who were negative both for *C. difficile* toxins and cultures (odds ratio 1.61; 95% CI 1.12–2.31;  $p = 0.01$ ) (Planche et al. 2013).

Is CDI any worse than other types of infective diarrhoea? Researchers in Austria found that patients with CDI were twice as likely to die while in hospital or within 30 days than patients with other types of infective diarrhoea

## care bundles and mandatory surveillance are needed both to control *Clostridium difficile* infection and to reduce mortality


(caused by norovirus campylobacter, adenovirus, salmonella or rotavirus) after adjustment for age, comorbidities and other infections (Schmid et al. 2013). From a public health perspective, CDI is estimated to cause 70% of all deaths due to gastroenteritis in the United States—ten times more than the next leading gastroenteritis pathogen, norovirus (Hall et al.

2012). According to recent CDC figures, CDI is associated with 29,300 deaths annually in the US (Lessa et al. 2015).

Mortality from CDI has been affected by changes in the epidemiology of the infection. The worldwide emergence of type 027 as a more virulent type with increased morbidity and mortality has been recognised since 2003 (Kuijper et al. 2006). Since then other highly virulent types have also been observed. These include types 018, 056 and 078 in Europe (Bauer et al. 2011; Walker et al. 2013), the last reportedly associated with higher mortality rates than type 027, and type 244 in Australia (Lim et al. 2014).

### Reducing CDI-Related Mortality

CDI can affect patients in all medical specialties. Efforts to reduce its impact on patients and health systems must involve all healthcare professionals, hospital/health institution managers, ancillary staff (including janitors) and patients themselves, not merely microbiologists and infection specialists. Approaches to reducing CDI-related mortality include strategic, health system-wide measures to optimise diagnosis, therapy and infection control according to recommendations (Crobach et al. 2009; Debast et al. 2014; Vonberg et al. 2008; Dubberke et al. 2014).



**Figure 2.** Annual number of death certificates mentioning *Clostridium difficile* infection (CDI), and of toxin-positive CDI cases (based on mandatory surveillance from 2007) in hospitals in England and Wales, 2001–2012. Data from the Office for National Statistics (2013) and Public Health England (2015). Also shown are key elements of the national programme to reduce CDI cases (Department of Health 2010; UK National Audit Office 2009).

### Diagnosis

Prompt CDI diagnosis can shorten the time to treatment and reduce empirical therapy, and enables infection control measures to be implemented (Barbut et al. 2014). A delay in CDI therapy owing to a failure of diagnosis may increase the risk of mortality, especially in patients with severe CDI (Berman et al. 2008). *C. difficile* testing policies and practices have improved in recent years, and yet almost a quarter of CDI episodes still go undiagnosed (Davies et al. 2014). Education directed to all healthcare staff regarding the appropriate management of patients with potentially infectious diarrhoea is therefore central to efforts to prevent and control CDI. For example, all staff members need to know that if they have a patient with potentially infectious diarrhoea, they should send a sample for laboratory testing, to include *C. difficile* tests, as soon as possible and manage the patient with appropriate infection control measures, e.g. contact precautions. Educating patients with regard to the possible implications of CDI and the need for them to report diarrhoea while in hospital, is also important.

### Therapy

Various experimental treatments for CDI are in development, ranging from new antibiotics to humanised anti-toxin monoclonal antibodies and faecal transplantations (Oldfield et al. 2014). Clinical trials have not been designed or powered to assess the benefit of therapy for CDI on mortality. In any event, regulatory Phase III

trials of new agents would not be the best tools to assess ‘real-world’ mortality benefits owing to the exclusion criteria employed. Retrospective observational evidence suggests that patients with CDI are more likely to die within 30 days if treatment fails to improve symptoms within 10 days (Kim et al. 2013). The use of oral vancomycin rather than metronidazole for severe CDI, as recommended (Debast et al. 2014), provides clinical benefit, although

## almost a quarter of CDI episodes still go undiagnosed

a numerical benefit on mortality did not reach statistical significance (Le et al. 2012). Recently, a large retrospective cohort study in the USA reported that patients with recurrent CDI had a 33% higher risk of death at 180 days compared with patients who had a primary CDI episode but no recurrence (hazard ratio 1.33; 95% CI 1.12–1.58;  $p=0.001$ ) (Olsen et al. 2015). A prospective UK study also found that patients with recurrent CDI were more likely to die within 1 year from the first episode (9/55; 16.4%) than were patients with non-recurrent infection (1/184; 0.5%;  $p<0.001$ ) (Taori et al. 2013).

Data on real-world treatment patterns in Europe are scarce. However, evidence from

the United States suggests that treatment and adherence to guidelines are suboptimal, especially in severe, complicated or recurrent CDI (Curtin et al. 2013). Although surgery can be life-saving in severe or complicated CDI (Bhangu et al. 2012), this depends critically on the indication, type and timing and further research is required.

### Infection Control and Prevention

Adherence to recommended measures for the control and prevention of CDI (Vonberg et al. 2008; Dubberke et al. 2014) is essential to reduce the burden of infection. While these measures are common to other HAIs, CDI-specific procedures, such as careful hand-washing using soap and water (rather than alcohol hand rubs), systematic glove wearing, sporicidal environmental decontamination and antibiotic stewardship, require specific education and resourcing. Importantly, antimicrobial stewardship programmes that reduce the use of high-risk antibiotics may contribute to a reduction in the rate of CDI cases. According to a recent meta-analysis of interventional studies, restrictive antibiotic stewardship policies halved the risk of CDI and had particular effect in elderly care settings (Feazel et al. 2014). Evidence suggests that gastric acid suppressants also increase the risk of CDI and should be considered in prevention strategies (Kwok et al. 2014).

Infection control and prevention bundles can reduce the incidence of CDI and control hospital outbreaks (Muto et al. 2007; Abbott et al. 2009). A bundle is a small set of evidence-based interventions for a defined patient segment/population and care setting that, when implemented together, will result in significantly better outcomes than when implemented individually (Resar et al. 2012). At a national level, a ‘high impact intervention’ bundle was implemented across the UK to prevent CDI and to control outbreaks caused by the type 027 strain (Department of Health 2010). This bundle (available online) combined elements of prudent antibiotic prescribing, correct hand hygiene, environmental contamination, personal protective equipment (e.g. gloves and aprons), and isolation or cohort nursing. It was introduced in 2010 as part of a national programme of actions (beginning in 2006) that include legislation on infection control in hospitals, hand hygiene campaigns, improvement teams, mandatory surveillance and reporting, diag-



# Are you relying on quality PCT results?

**Well established clinical cut-offs and algorithms are based on original, high sensitivity B·R·A·H·M·S PCT™ methods.** B·R·A·H·M·S PCT™, as the original Procalcitonin method, has been demonstrated to improve the accuracy of diagnosis and risk assessment in bacterial infection and sepsis<sup>1</sup> and has the sensitivity to guide antibiotic therapy-related decisions<sup>2</sup>. When saving lives, quality is a necessity, not a compromise. **For safe clinical decision making**, only rely on quality Procalcitonin assays. **Be sure, be safe.**

## B·R·A·H·M·S PCT assays

• For more information visit us at [thermoscientific.com/procalcitonin](http://thermoscientific.com/procalcitonin)



### Automated sensitive assays

B·R·A·H·M·S PCT™ sensitive KRYPTOR™  
ADVIA Centaur® B·R·A·H·M·S PCT™  
ELECSYS® B·R·A·H·M·S PCT™  
LIAISON® B·R·A·H·M·S PCT™ II GEN  
Lumipulse® G B·R·A·H·M·S PCT™  
VIDAS® B·R·A·H·M·S PCT™

### Manual assay

B·R·A·H·M·S PCT™ LIA

### POC tests

B·R·A·H·M·S PCT-Q™  
Samsung IB B·R·A·H·M·S PCT™

nosis and testing guidelines and a network of ribotyping laboratories (UK National Audit Office 2009). The annual number of CDI cases in England has decreased by approximately 80% since mandatory reporting was introduced in 2007/8, with a corresponding fall in the number of deaths (Fig. 2) (Office for National Statistics 2012; Public Health England 2015).

### Care Quality Bundle for CDI Management

While bundles exist for CDI prevention and infection control, there is a limited interventional evidence base for a corresponding bundle designed to improve CDI management in order to avoid complications, recurrence and mortality. Nevertheless, an intervention programme was recently reported to have reduced delays in the initiation of CDI therapy and increased adherence to practice guidelines (Jury et al. 2013). This programme comprised physician education on CDI diagnostic testing and treatment recommendations and a CDI order menu (including diagnostic and therapeutic recommendations) implemented in the electronic medical record system. A CDI stewardship team (comprising a nurse practitioner and an infectious-diseases physician, with intermittent assistance from an infectious-diseases fellow and an infectious-diseases pharmacist) was notified by the microbiology laboratory of all positive *C. difficile* test results. This team reviewed electronic medical records and either provided initial treatment recommendations or, if treatment was ordered, provided feedback to physicians if management was not in accordance with guidelines. Finally, medical records were reviewed for a sample of patients prescribed empirical CDI therapy, and feedback was provided to physicians on adherence to the relevant recommendation on empirical therapy. Other workers have described a severity-based treatment policy that increased vancomycin use (according to guidelines) and reduced the rate of refractory disease in patients with severe CDI (Jardin et al. 2013). Such a bundle is not a 'magic bullet', but is part of a proposed approach that offers particular benefit when current practice is poor. Further research is essential to define the elements that should be included in bundles to improve the quality of care for CDI.

### Using CDI as a Care Quality Indicator

The implementation and effectiveness of a CDI care bundle should ideally be measured within quality improvement frameworks using both process indicators (e.g. the percentage of patients who commence treatment on the same day as diagnosis and the percentage of patients treated according to current guidelines) and outcome indicators (in-hospital or 30-day mortality and frequency of complications).

CDI is a healthcare facility-wide problem linked to all factors responsible for HAIs in general, including antimicrobial use and overuse, improper or inadequate handwashing, lapses in infection control procedures, poor decontamination of the healthcare environment, a lack of education and training and understaffing. The incidence of healthcare-associated CDI itself is a potentially useful routine marker of care quality and patient safety and yet it is little used in Europe. It has only been used as a national performance measure, and is mandatorily and publicly reported at hospital level, in the UK (since 2004) (Public Health England 2015; Department of

1. Soni N.J. et al., J Hosp Med 2013;8 (9): 530-40. 2. Meisner, M., Procalcitonin – Biochemistry and Clinical Diagnosis, UNI-MED (Bremen) 2010; ISBN 978-3-8374-1241-3.

© 2016 Thermo Fisher Scientific Inc. All rights reserved. B·R·A·H·M·S PCT™ and all other trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. ADVIA Centaur® is a registered and protected trademark belonging to Siemens Healthcare Diagnostics. ADVIA Centaur® B·R·A·H·M·S PCT™ is a product of Siemens Healthcare Diagnostics licensed from Thermo Fisher Scientific. Elecsys® is a registered and protected trademark belonging to Roche or one of its subsidiaries. Elecsys® B·R·A·H·M·S PCT™ is a product of Roche licensed from Thermo Fisher Scientific. LIAISON® is a registered and protected trademark belonging to DiaSorin S.p.A. LIAISON® B·R·A·H·M·S PCT™ II GEN is a product of DiaSorin S.p.A licensed from Thermo Fisher Scientific. Lumipulse® is a registered trademark of Fujirebio Inc. in Japan and in other countries. Lumipulse® G B·R·A·H·M·S PCT™ is a product of Fujirebio Inc. licensed from Thermo Fisher Scientific. Samsung IB B·R·A·H·M·S PCT™ is a product of Samsung C&T Corporation licensed from Thermo Fisher Scientific. VIDAS® is a registered trademark of bioMérieux S.A. or one of its subsidiaries. VIDAS® B·R·A·H·M·S PCT™ is a product of bioMérieux licensed from Thermo Fisher Scientific. KRYPTOR is a registered trademark of CIS bio international, licensed for use by B·R·A·H·M·S, a part of Thermo Fisher Scientific. Thermo Fisher Scientific products are distributed worldwide; not all intended uses and applications mentioned in this printing are registered in every country.

Health 2012). In Ireland, CDI has been an indicator in the national service plan since 2013 (F. Fitzpatrick, personal communication). Public reporting of CDI is also mandatory in Canada where in common with the UK it has been accompanied by a reduction in cases (Daneman et al. 2012). We would argue that mandatory, centralised, national collection and public reporting of hospital-level CDI incidence rates (with the origin or case, i.e. healthcare-associated or community-associated) would benefit CDI control, while acknowledging that such data should be collected using standardised methods and subject to risk adjustment and external audit.

There is a consensus among European infectious disease experts that public reporting of HAI indicators can benefit hospitals (Martin et al. 2013). Whether they directly benefit or influence patients themselves, and how indicators should be chosen and implemented, are more contentious questions. In 2009 the European Council recommended the development of a set of reliable and comparable patient safety indicators to help identify safety problems, evaluate the effectiveness of interventions aimed at improving safety, and facilitate mutual learning between Member States (Council of the European Union 2009). National performance indicators for HAIs in hospitals have since been developed by collaborative European projects (Cookson et al. 2011). However, according to the European Commission, in 2012 data on a limited and variable set of HAI indicators were made publicly available at the hospital level only in Denmark, France, Ireland, Luxembourg, Norway and the UK (European Commission 2012).

Generally, infection control experts are reported to favour structure indicators (e.g. the existence of national programmes, committees, guidelines and resources) and process indicators (e.g. alcohol-based hand-rub consumption) rather than outcome indicators (e.g. HAI incidence rates) (Martin et al. 2013). Concerns regarding outcomes data include the potential for mis-interpretation (due for example to inter-site differences in the patients monitored or the surveillance methods used) and under-reporting. Experts in France have proposed conditions for implementing and reporting performance indicators, namely a broad debate on their benefits and drawbacks, a test period, the avoidance of extra workload for infection control teams and the use of quality and validity control measures (French Society for Hospital Hygiene 2013).

### Conclusion

There is now clear evidence that CDI increases the risk of death in hospitalised patients, especially among vulnerable groups such as the elderly and immunocompromised. This substantial and often preventable threat to patient safety warrants specific attention by healthcare policymakers, and this will become important as the population ages. Addressing

## the incidence of healthcare-associated CDI is a potentially useful routine marker of care quality and patient safety yet is little used in Europe

CDI is not a matter for microbiologists and infection specialists alone, as the infection threatens patients in all medical specialties and sites of care. It requires organisational leadership and commitment, with system-wide prioritisation of prompt and accurate diagnosis, and the implementation and audit of guidelines-led treatment and infection control measures, and continued European, national and local surveillance. Care bundles designed to improve CDI management and avoid complications, recurrence and mortality should be implemented within frameworks for improving quality and patient safety and monitored using appropriate indicators. We would also argue that mandatory centralised national collection and public reporting of hospital-level CDI incidence rates would benefit CDI control.

### Conflict of Interest

FB has received fees as speaker and member of advisory boards from Pfizer, Novartis, Astellas Pharma Europe Ltd, MSD, Cepheid, bioMérieux and Summit. JC has received fees as speaker and member of advisory boards from Astellas Pharma Europe Ltd, AstraZeneca, Pfizer and Novartis. OAC is supported by the German Federal Ministry of Research and Education (BMBF grant 01KN1106) and the European Commission, and has received research grants from, is an advisor to, or received lecture honora from Actelion, Astellas Pharma Europe Ltd,

Cubist, Genzyme, MSD, Optimer, Sanofi Pasteur, Summit, and Viropharma. EJK has received fees as speaker and/or member of advisory boards from Pfizer, Novartis, Astellas Pharma Europe Ltd and MSD. NP has received fees as speaker and member of advisory boards from Pfizer, Novartis, Astellas Pharma Europe Ltd, MSD, Johnson & Johnson and Carefusion.

### Authors' Contributions

This paper was born from discussions at meetings of CDI Europe, an expert-led initiative aiming to translate research on CDI into meaningful policy responses to help improve patient outcomes, supported by Medline literature searches using relevant key words. All authors were involved at each stage, from the initial proposal, through review and input into the outline and multiple drafts to final approval.

### Acknowledgements

All authors are members of the CDI Europe group. This manuscript was reviewed by the following additional members of the CDI Europe group: Mark Wilcox (Leeds, UK: Chair), Franz Allerberger (Vienna, Austria), Fidelma Fitzpatrick (Dublin, Ireland), Elisabeth Nagy (Szeged, Hungary), Carl Eric Nord (Stockholm, Sweden), Maja Rupnik (Maribor, Slovenia).

Editorial assistance was provided by Interel Ltd., funded by Astellas Pharma Europe Ltd. Astellas Pharma Europe Ltd provided editorial assistance for the final paper by way of a factual accuracy check only.

The development of this paper was supported by Astellas Pharma Europe Ltd. Medical Writer attendance at the review meetings was funded by Astellas Pharma Europe Ltd, as was all subsequent time spent working with the authors to produce and submit the manuscript. The views expressed are those of the authors and not necessarily of Astellas Pharma Europe Ltd. ■

### Abbreviations

CDI *Clostridium difficile* infection  
 CDC Centers for Disease Control and Prevention  
 CI confidence intervals  
 ECDC European Centre for Disease Prevention and Control  
 HAI healthcare-associated infection

For full references, please email [editorial@icu-management.org](mailto:editorial@icu-management.org) or visit [icu-management.org](http://icu-management.org) or use the article QR code.